The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
